Bilcare Technologies has entered into agreement with global and domestic pharma companies such as MSD, Ranbaxy, Mankind and Panacea to offer its nanotechnology-based anti-counterfeit technology.

"We are working to implement this technology for the Delhi police. It is also being deployed in leading pharmaceutical and agrochemical companies in India," said Mohan Bhandari, MD, Bilcare.

The technology is capable of anti-counterfeiting, security and brand protection to products across a number of industries. The company developed nonClonableID based on nano technology which is a unique fingerprint that offers protection to the products.

According to Bilcare, the technology when implemented to the pharma sector will increase the price of pack's cost by around Rs 1.50- 2 for the manufacturer. The technology is capable of tracking the product in stages of its supply chain.

The company aims to commercialize the technology on the end consumer level. In the international markets, the technology has been accepted by a wine producer in the US and security department for the president of Indonesia.

Sam Pitroda, the advisor on Public Information Infrastructure and Innovations to Prime Minister Manmohan Singh has advised the company to have a proper patent otherwise larger companies will try to get the innovative technology.